In terms of the newest collaboration, the health care professionals said they decided that having all the services under one ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

Tesla boss Elon Musk seems to be on a mission to conquer the world, and even Mars. But his odd-hour rants, alleged Nazi ...

Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...

Myers Squibb Company, Johnson & Johnson, Bausch Health Companies Inc, AbbVie Inc. Read 's Market Analysis on Investing.com ...

Johnson & Johnson has priced its new Spravato nasal spray for treatment-resistant depression (TRD) too high to offer value for money, says a US cost-effectiveness body. The Institute for Clinical ...

The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

Q4 2024 Earnings Call Transcript March 17, 2025 Operator: Good morning, ladies and gentlemen, and welcome to the NRx Pharmaceuticals 4Q and Full Year 2024 Earnings Call. At this time, all lines are in ...

Low back pain affects an estimated one in four American adults and is the leading contributor to disability globally. In most ...

Current FDA approval of this adaptive system is for the treatment of Parkinson’s only, not essential tremor, dystonia (a ...

Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...